New treatment target verification for myelodysplastic syndrome

June 08, 2020

A research group from Kumamoto University, Japan analyzed the pathophysiology of myelodysplastic syndrome (MDS), a blood cancer that presents often in the elderly, and found the presence of the transcription factor RUNX3, thereby revealing a cancer growth function for what had been considered a tumor suppressor. Additional analyses of human MDS cells and model mice found an abnormal gene expression mechanism linked to the initiation and propagation of MDS stem cells, and confirmed RUNX3 as a new therapeutic target.

MDS is a refractory cancer that is resistant to anticancer drugs. It originates from hematopoietic stem cells and causes hematopoietic failure. Recent advances in comprehensive DNA sequencing analysis have largely revealed the major genetic mutations within MDS but much remains unknown about the mechanisms that cause it. Thus, the International Research Center for Medical Sciences (IRCMS) research group turned their focused toward the transcription factor RUNX3 and investigated its role in the development of MDS.

They first analyzed the correlation between RUNX3 expression levels in human MDS cells and life prognosis, and confirmed that patients with higher RUNX3 expression had a worse prognosis. Next, since RUNX3 expression in human MDS cells has a high frequency of mutation in TET2 gene, they created RUNX3-expressing MDS model mice deficient in the TET2 gene. RUNX3-expressing TET2-deficient MDS cells were found to suppress the expression level and function of RUNX1, a transcription factor in the same gene family as RUNX3 and is essential for normal hematopoiesis. This indicates a new mechanism of cancer development that suppresses normal functions through interactions between family genes. The researchers also found that RUNX3 cooperates with the MYC gene, a known oncogene, to grow MDS cells. Inhibition of MYC function significantly suppressed the proliferation of RUNX3-expressing cells.

"Further progress in future research is expected to lead to the development of new therapeutic methods targeting the transcription factor RUNX3 in the refractory cancer myelodysplastic syndrome," said Professor Goro Sashida who lead this study. "Our results are also expected to be beneficial in the study of other hematological cancers where the transcription factor RUNX plays an important role such as Down's syndrome-related leukemia."
This research was posted online in Cancer Research on 27 April 2020.


Yokomizo-Nakano, T., Kubota, S., Bai, J., Hamashima, A., Morii, M., Sun, Y., ... Sashida, G. (2020). Overexpression of RUNX3 represses RUNX1 to drive transformation of myelodysplastic syndrome. Cancer Research, canres.3167.2019. doi:10.1158/0008-5472.can-19-3167

Kumamoto University

Related Tumor Suppressor Articles from Brightsurf:

New results on the function of the tumor suppressor HERC protein
The RAF protein could be a therapeutical target to treat the tumor growth in regulated pathways by the p38 protein, according to a new study published in the journal Scientific Reports by a team of experts of the Faculty of Medicine and Health Sciences of the University of Barcelona and the Bellvitge Institute for Biomedical Research (IDIBELL).

New function for potential tumor suppressor in brain development
New research from the group of Simon Hippenmeyer, professor at the Institute of Science and Technology Austria (IST Austria), has now uncovered a novel, opposite role for Cdkn1c.

Researchers determine how a major tumor suppressor pathway becomes deactivated
The Hippo pathway is an important biological tumor suppressor program that controls cell growth and organ size in humans.

Nanoparticle therapeutic restores function of tumor suppressor in prostate cancer
Leveraging advances in mRNA and nanotechnology, investigators demonstrate that tumor suppressor PTEN can be restored in preclinical models of prostate cancer.

Discovery of a new tumor suppressor previously thought to be an oncogene
A gene that has for decades been considered a tumor promoter, the PLK1 gene, can also perform the exact opposite function: halting the development of cancer.

Unraveling role of tumor suppressor in gene expression & ovarian tumorigenesis
The tumor suppressor protein ARID1A controls global transcription in ovarian epithelial cells, according to new research conducted at The Wistar Institute, which provided mechanistic insight into tumorigenesis mediated by ARID1A loss in ovarian cancer.

Tumor suppressor protein plays key role in suppressing infections
Researchers have found that a previously uncharacterized tumor-suppressor protein plays an important role in the functioning of the immune system.

Tumor suppressor protein targets liver cancer
Salk Institute scientists, together with researchers from Switzerland's University of Basel and University Hospital Basel, discovered a protein called LHPP that acts as a molecular switch to turn off the uncontrolled growth of cells in liver cancer.

Stanford-led study uncovers mutation that supercharges tumor-suppressor
Stanford scientists have found an answer to one of cancer biology's toughest and most important questions: how does the body suppress tumors?

Injecting activator of a powerful tumor suppressor directly into the cancer increases tumor destruction, decreases toxicity
Directly injecting a tumor with an agent that activates a natural, powerful tumor suppressor enhances the drug's capacity to attack the tumor both locally and where it spreads, scientists report in the journal Cancer Research.

Read More: Tumor Suppressor News and Tumor Suppressor Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to